左诗意 博士后
E-mail: zuoshiyi@aliyun.com
教育/科研工作经历
2025.7-至今 华南理工大学 生物医学科学与工程学院 博士后
2021.09-2025.07 沈阳药科大学 药剂学 博士
2024.02-2025.02 阿德莱德大学（澳洲） 化学工程学院 公派留学
2018.09-2021.07 沈阳药科大学 药剂学 硕士
2014.09-2018.07 沈阳药科大学 药物制剂 学士
科研成果
以第一作者和共同第一作者身份在Cell Reports Medicine和Small等期刊发表9篇SCI论文，获得授权发明专利5项。
科研方向
主要从事纳米载体递送生物大分子用于肿瘤免疫治疗的研究。
代表性研究论文
1. Zuo S, Liu T, Li L,et al. Tetrasulfide bond boosts the anti-tumor efficacy of dimeric prodrugnanoassemblies. Cell Reports Medicine, 2024, 5(3):101432.
2. Zuo S*, Sun B*, YangY, et al. Probing the superiority of diselenium bond on docetaxel dimeric prodrugnanoassemblies: small roles taking big responsibilities. Small, 2020,16, 2005039.
3. Zuo S, Wang Q, Su X,et al. Bioinspired prodrug nanoassemblies with dual PEGylation and membrane-coatingstrategies. Nano Research, 2025, 10.26599/NR.2025.94907570.
4. Zuo S, Song J, ZhangJ, et al. Nano-immunotherapy: the application of nanotechnology in each stageof cancer cellular immunity. Theranostics, 2021, 11(15):7471-7487.
5. Yang Y*, Zuo S*,Zhang J, et al. Prodrug nanoassemblies bridged by Mono-/Di-/Tri-sulfide bonds. NanoToday, 2022, 44:101480.
6. Xu H*, Zuo S*, WangD, et al. Cabazitaxel prodrug nanoassemblies with branched chain modifications.Journal of Controlled Release, 2023, 360:784–795.
7. Gao Y*, Zuo S*, Li L,et al. The length of disulfide bond-containing linkages impacts the oral absorptionand antitumor activity of paclitaxel prodrugs-loaded nanoemulsions. Nanoscale,2021,13, 10536-10543.
8. Yu Y*, Zuo S*, SongJ*, et al. pH-sensitive doxorubicin-fatty acid prodrugs. Nano Research,2024, 17(6):5491–5500.
9. Wang Q*, Zuo S*,Zheng S, et al. Branched module-modified SN38 prodrug nanoassemblies. NanoResearch, 2025, 18(1):94907011–14.